pharmaceutical investing Ritter Pharmaceuticals Completes Dosing of Last Patient in Pivotal 557-Subject Phase 3 Clinical Trial
pharmaceutical investing Ritter Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance
Syntholene Energy Corp. Appoints Former Suncor, Shell Operations Executive Marc Mageau to Advisory Board
Angkor Resources' Subsidiary Implements Playgrounds For Rural Schools In Block VIII Drilling Area, Cambodia
